Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.
Prondzynski M, Lemoine MD, Zech AT, Horváth A, Di Mauro V, Koivumäki JT, Kresin N, Busch J, Krause T, Krämer E, Schlossarek S, Spohn M, Friedrich FW, Münch J, Laufer SD, Redwood C, Volk AE, Hansen A, Mearini G, Catalucci D, Meyer C, Christ T, Patten M, Eschenhagen T, Carrier L. Prondzynski M, et al. Among authors: patten m. EMBO Mol Med. 2022 Aug 8;14(8):e16423. doi: 10.15252/emmm.202216423. EMBO Mol Med. 2022. PMID: 35938313 Free PMC article. No abstract available.
Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.
Prondzynski M, Lemoine MD, Zech AT, Horváth A, Di Mauro V, Koivumäki JT, Kresin N, Busch J, Krause T, Krämer E, Schlossarek S, Spohn M, Friedrich FW, Münch J, Laufer SD, Redwood C, Volk AE, Hansen A, Mearini G, Catalucci D, Meyer C, Christ T, Patten M, Eschenhagen T, Carrier L. Prondzynski M, et al. Among authors: patten m. EMBO Mol Med. 2019 Dec;11(12):e11115. doi: 10.15252/emmm.201911115. Epub 2019 Nov 3. EMBO Mol Med. 2019. PMID: 31680489 Free PMC article.
The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.
Thottakara T, Friedrich FW, Reischmann S, Braumann S, Schlossarek S, Krämer E, Juhr D, Schlüter H, van der Velden J, Münch J, Patten M, Eschenhagen T, Moog-Lutz C, Carrier L. Thottakara T, et al. Among authors: patten m. J Mol Cell Cardiol. 2015 Oct;87:214-24. doi: 10.1016/j.yjmcc.2015.08.020. Epub 2015 Sep 3. J Mol Cell Cardiol. 2015. PMID: 26343497
Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.
Prondzynski M, Krämer E, Laufer SD, Shibamiya A, Pless O, Flenner F, Müller OJ, Münch J, Redwood C, Hansen A, Patten M, Eschenhagen T, Mearini G, Carrier L. Prondzynski M, et al. Among authors: patten m. Mol Ther Nucleic Acids. 2017 Jun 16;7:475-486. doi: 10.1016/j.omtn.2017.05.008. Epub 2017 May 17. Mol Ther Nucleic Acids. 2017. PMID: 28624223 Free PMC article.
FHL2 expression and variants in hypertrophic cardiomyopathy.
Friedrich FW, Reischmann S, Schwalm A, Unger A, Ramanujam D, Münch J, Müller OJ, Hengstenberg C, Galve E, Charron P, Linke WA, Engelhardt S, Patten M, Richard P, van der Velden J, Eschenhagen T, Isnard R, Carrier L. Friedrich FW, et al. Among authors: patten m. Basic Res Cardiol. 2014;109(6):451. doi: 10.1007/s00395-014-0451-8. Epub 2014 Oct 31. Basic Res Cardiol. 2014. PMID: 25358972 Free PMC article.
165 results